NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Coleman CI, Baker WL, Kluger J, et al. Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Oct. (Comparative Effectiveness Reviews, No. 18.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease

Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].

Show details

Appendix CAdditional Evidence Tables and Analyses

Abbreviations for Appendix C

ACE

Angiotensin Converting Enzyme

ACEI

Angiotensin Converting Enzyme Inhibitor

ADE

Adverse Drug Event

AHR

Adjusted Hazard Ratio

AMSTAR

Assess the Methodological quality of SysteMAtic Review

APRES

Angiotensin-converting Enzyme inhibition Post Revascularization Study

ARB

Angiotensin Receptor Blocker

CABG

Coronary Artery Bypass Grafting

CAD

Coronary Artery Disease

CAMELOT

Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis

CCB

Calcium Channel Blocker

CHF

Congestive Heart Failure

CI

Confidence Interval

CV

Cardiovascular

DM

Diabetes Mellitus

EKG

Electrocardiogram

EUROPA

EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease

FOSIDIAL

FOSInopril in DIALysis

F/U

Follow-Up

GRADE

Grading of Recommendations Assessment, DEvelopment

HF

Heart Failure

HOPE

Heart Outcomes Prevention Evaluation

HR

Hazard Ratio

HTN

Hypertension

IC

Intermittent Claudication

IHD

Ischemic Heart Disease

IMAGINE

Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme

JMIC-B

Japan Multicenter Investigation for Cardiovascular Diseases-B

LVEF

Left Ventricular Ejection Fraction

LVH

Left Ventricular Hypertrophy

MARCATOR

Multicenter American Research trial with Cilazapril After angioplasty to prevent Transluminal coronary Obstruction and Restenosis

MI

Myocardial Infarction

N/A

Not Applicable

NR

Not Reported

ONTARGET

ONgoing Telmisartan Alone in combination with Ramipril Global Endpoint Trial

OR

Odds Ratio

PARIS

Effect of ACE inhibitors on angiographic restenosis after coronary stenting

PART-2

Prevention of Atherosclerosis with Ramipril Trial-2

PCI

Percutaneous Coronary Intervention

PEACE

Prevention of Events with Angiotensin Converting Enzyme Inhibition

PTCA

Percutaneous Transluminal Coronary Angioplasy

PVD

Peripheral Vascular Disease

QUIET

Quinapril Ischemic Event Trial

RCT

Randomized Controlled Trial

RR

Relative Risk

SB

Single Blind

SCAT

Simvastatin/enalapril Coronary Atherosclerosis Trial

SMILE-ISCHEMIA

Survival of Myocardial Infarcton Long-term Evaluation-ISCHEMIA

SMT

Standard Medical Therapy

TIA

Transient Ischemic Attack

TRANSCEND

Telmisartan Ransomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease

SCR

Scientific Resource Center

Appendix Table 1. Pertinent systematic reviews

Appendix Table 2. KQ1 Total mortality—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 3. KQ1 Cardiovascular mortality—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 4. KQ1 Nonfatal myocardial infarction—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 5. KQ1 Stroke—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 6. KQ1 Composite—Cardiovascular mortality, nonfatal myocardial infarction, or stroke—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 7. KQ1 Atrial Fibrillation - Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 8. KQ1 Hospitalizations—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 9. KQ1 Hospitalization for angina—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 10. KQ1 Hospitalization for heart failure—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 11. KQ1 Revascularization—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Figure 1. KQ1 Total mortality ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 2. KQ1 Total mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled and open-label trials in patients with stable ischemic heart disease

Appendix Figure 3. KQ1 Total mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled & open-label trials in patients with stable ischemic heart disease risk equivalents

Appendix Figure 4. KQ1 Cardiovascular mortality ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 5. KQ1 Cardiovascular mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled or open-label trials in patients with stable ischemic heart disease

Appendix Figure 6. KQ1 Nonfatal myocardial infarction ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 7. KQ1 Nonfatal myocardial infarction sensitivity analysis—Meta-analysis of randomized placebo-controlled + open-label trials in patients with stable ischemic heart disease

Appendix Figure 8. KQ1 Stroke ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 9. KQ1 Stroke sensitivity analysis—Meta-analysis of randomized placebo-controlled + open-label trials in patients with stable ischemic heart disease

Appendix Figure 10. KQ1 Composite of cardiovascular mortality, nonfatal myocardial infarction and stroke ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 11. KQ1 Hospitalization for angina ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 12. KQ1 Hospitalization for angina sensitivity analysis—Meta-analysis of randomized placebo-controlled + open-label trials in patients with stable ischemic heart disease

Appendix Figure 13. KQ1 Hospitalization for heart failure ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 14. KQ1 Hospitalization for heart failure sensitivity analysis—Meta-analysis of randomized placebo-controlled + open-label trials in patients with stable ischemic heart disease

Appendix Figure 15. KQ1 Revascularization ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 16. KQ1 Revascularization subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease undergoing coronary artery bypass grafting surgery only

Appendix Figure 17. KQ1 Revascularization subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease undergoing percutaneous coronary intervention only

Appendix Figure 18. KQ1 Revascularization sensitivity analysis—Meta-analysis of randomized placebo-controlled or open-label trials in patients with stable ischemic heart disease

Appendix Table 12. KQ3 Total mortality—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 13. KQ3 Cardiovascular mortality—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 14. KQ3 Nonfatal myocardial infarction—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 15. KQ3 Stroke—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 16. KQ3 Composite: Cardiovascular mortality, nonfatal myocardial infarction, or stroke—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 17. KQ3 Atrial fibrillation—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 18. KQ3 Hospitalization for angina—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 19. KQ3 Hospitalization for heart failure—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 20. KQ3 Revascularization—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Figure 19. KQ3 Total mortality ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 20. KQ3 Total mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled or open-label trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 21. KQ3 Total mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled trials utilizing intention-to-treat methodologies in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 22. KQ3 Total mortality subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, percutaneous procedure only

Appendix Figure 23. KQ3 Cardiovascular mortality ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 24. KQ3 Cardiovascular mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled or open-label trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 25. KQ3 Cardiovascular mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled trials utilizing intention-to-treat methodologies in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 26. KQ3 Cardiovascular mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled or open-label trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, percutaneous procedure only

Appendix Figure 27. KQ3 Nonfatal myocardial infarction ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 28. KQ3 Nonfatal myocardial infarction sensitivity analysis—Meta-analysis of randomized placebo-controlled + open-label trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 29. KQ3 Nonfatal myocardial infarction sensitivity analysis—Meta-analysis of randomized placebo-controlled trials utilizing intention-to-treat methodologies in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 30. KQ3 Nonfatal myocardial infarction subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, percutaneous procedure only

Appendix Figure 31. KQ3 Stroke ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 32. KQ3 Stroke sensitivity analysis—Meta-analysis of randomized placebo-controlled or open-label trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 33. KQ3 Stroke sensitivity analysis—Meta-analysis of randomized placebo-controlled trials utilizing intention-to-treat methodologies in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 34. KQ3 Hospitalization for angina ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 35. KQ3 Hospitalization for angina sensitivity analysis—Meta-analysis of randomized placebo-controlled or open-label trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 36. KQ3 Hospitalization for angina sensitivity analysis—Meta-analysis of randomized placebo-controlled trials utilizing intention-to-treat methodologies in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 37. KQ3 Revascularizations ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 38. KQ3 Revascularizations sensitivity analysis—Meta-analysis of randomized placebo-controlled or open-label trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 39. KQ3 Revascularizations sensitivity analysis—Meta-analysis of randomized placebo-controlled trials utilizing intention-to-treat methodologies in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Appendix Figure 40. KQ3 Revascularizations subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, percutaneous procedure only

Appendix Figure 41. KQ3 Revascularizations subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, coronary artery bypass grafting surgery only

Appendix Table 21. KQ4 Run-in phase data—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 22. KQ4 Study withdrawals—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease.

Appendix Table 23. KQ4 Withdrawals due to adverse events—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 24. KQ4 Hypotension—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 25. KQ4 Syncope—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 26. KQ4 Cough—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 27. KQ4 Angioedema—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 28. KQ4 Hyperkalemia—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 29. KQ4 Blood dyscrasias—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 30. KQ4 Rash—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Figure 42. KQ4 Withdrawal due to adverse events subgroup ACEI analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Figure 43. KQ4 Hypotension ACEI subgroup analysis—Meta-analysis of randomized placebo-controlled trials in patients with stable ischemic heart disease

Appendix Table 31. KQ6 Run-in phase date—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 32. KQ6 Study withdrawals—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 33. KQ6 Withdrawals due to adverse events—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 34. KQ6 Hypotension—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 35. KQ6 Syncope—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 36. KQ6 Cough—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 37. KQ6 Angioedema—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 38. KQ6 Hyperkalemia—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 39. KQ6 Rash—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Table 40. KQ6 Blood dyscrasias—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Appendix Figure 44. KQ6. Withdrawals due to adverse events sensitivity analysis—Meta-analysis of randomized placebo-controlled + open-label trials in patients with stable ischemic heart disease

Appendix Figure 45. KQ6. Cough sensitivity analysis—Meta-analysis of randomized placebo-controlled + open-label trials in patients with stable ischemic heart disease

Appendix Table 41. KQ1—Strength of evidence grading

Appendix Table 41a. KQ1—Pertinent subgroup strength of evidence grading

Appendix Table 42. KQ2—Strength of evidence grading

Appendix Table 43. KQ3—Strength of evidence grading

Appendix Table 44. KQ4—Strength of evidence grading

Appendix Table 45. KQ5—Strength of evidence grading

Appendix Table 46. KQ6—Strength of evidence grading

Appendix Table 47. KQ7—Strength of evidence grading

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (5.0M)
  • Disable Glossary Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...